New $1.5B ADC manufacturing facility & 9 more updates...👇
🤝 → M&A activity
HI-Bio™ & Biogen
🤝 Biogen to acquire HI-Bio for $1.8B acquisition will strengthen Biogen’s immunology portfolio. Acquisition is expected to close in Q3 2024.
AstraZeneca
🤝 Invested $1.5B to build its first end-to-end ADC manufacturing facility in Singapore. This state-of-the-art facility will cover the entire ADC production process at a commercial scale and is expected to be operational by 2029.
—
🎯 → Approvals
Amphastar
🎯 FDA approves albuterol sulfate for bronchospasm treatment and prevention.
—
🔬 → New data
Arrowhead Pharmaceuticals
🔬 Ph1/2 trial of ARO-RAGE treatment in patients with asthma demonstrated a high level of gene knockdown, with serum reduction reaching up to 88%.
Dyne Therapeutics
🔬 New data reported from ACHIEVE Ph1/2 trial of DYNE-101 in DM1 and DELIVER Ph1/2 trial of DYNE-251 in DMD demonstrating a significant impact on key disease biomarkers and improvement in multiple functional endpoints.
Esperion Therapeutics
🔬 Bempedoic acid met the primary endpoint in a Ph3 trial in Japan for the treatment of hypercholesterolemia, demonstrating a statistically significant reduction in LDL cholesterol compared to placebo.
Gilead Sciences
🔬 Interim Ph3 results reported from the seladelpar treatment in patients with PBC showing improved markers of liver disease progression and reduced itching.
Citius Pharmaceuticals
🔬 Mino-Lok antibiotic lock solution successfully met primary and secondary endpoints in a Ph3 trial, significantly reducing catheter-related bloodstream infections and microbial colonization in patients with central venous catheters.
Zealand Pharma
🔬 Reported positive topline results from the DREAM Ph2 trial of its GLP-1/GLP-2 receptor dual agonist, dapiglutide. Low doses of dapiglutide led to a mean weight loss of up to 4.3% after 12 weeks and were well-tolerated, supporting its potential as a treatment for obesity.
Cogent Biosciences
🔬 Reported positive updated data from the ongoing Ph3 PEAK trial at ASCO, showing a median progression-free survival of 10.2 months for bezuclastinib + sunitinib in patients with gastrointestinal stromal tumors (GIST). The combination therapy continues to show a promising safety profile.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
May 20-24, 2024
Article History:
RF, DV, DG, EV (05/24/24)
Comments